Merck will pay $106m for a 15% stake in NGM as part of a five-year, $450m diabetes and obesity treatment development deal with the biotechnology company.

US-based biotechnology company NGM Biopharmaceuticals has secured a collaboration agreement with pharmaceutical company Merck that will see it receive $450m over the next five years, according to Forbes.

Merck will provide NGM with $106m in equity funding in exchange for a 15% stake, as well as a $94m upfront cash payment. It will supply the remaining money in yearly $50m instalments that will support research and development at NGM.

Merck will gain options on preclinical drug candidates through the deal…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?